SCHEMBL717701

SCHEMBL717701

CCOC(=O)CCNC(=O)c1ccc(NC(c2nc3ccc(OC)cc3n2C)C2CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
NR1H4 Q96RI1 1/20 0.40
CYP2C9 P11712 1/20 0.39
GCG P01275 2/20 0.39
TP53 P04637 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MDM2 Q00987 1/20 0.38
THRB P10828 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
BRD4 O60885 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403102 0.91 GCG (0.45) NR1H4GCGTP53NPC1RAB9A
SCHEMBL721554 0.87 IDH1 (0.42) MEN1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL718794 0.83 NR1H4 (0.45) MEN1KMT2ANR1H4TP53ALDH1A1
SCHEMBL722458 0.83 NR1H4 (0.45) MEN1KMT2ACYP2C19CYP1A2MTNR1A
SCHEMBL3402066 0.79 NR1H4 (0.40) MEN1KMT2AMTNR1AMTNR1BNR1H4
SCHEMBL721583 0.79 GCG (0.42) MEN1KMT2AGCG
SCHEMBL718932 0.78 GCGR (0.49) GCG
SCHEMBL717292 0.77 GCG (0.46) MEN1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL719981 0.76 MEN1 (0.45) MEN1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL721582 0.74 GCGR (0.46) GCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MEN1 444/4885KMT2A 1298/4885CYP3A4 834/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MEN1 444/4885KMT2A 1298/4885CYP3A4 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.